IVX’s disease areas of interest in infectious diseases

Early stage pre-clinical results have yielded positive screening results from in vitro studies of Photosoft on the inhibition of multiple strains of viruses and bacteria. These tests were carried out by the Australian Centre for Antimicrobial Resistance Ecology (ACARE), which is part of the University of Adelaide, and Viroclinics-DDL (Cerba Research).

Invion subsequently signed collaboration agreements with South Korean-based Dr. I&B Co., Ltd. (Dr.inB) to develop Photosoft™ for the treatment of the Human Papilloma Virus (HPV).


Similar to the agreement with Hanlim Pharma Co., Ltd., Dr.inB will fund all Proof-of-Concept in vitro and/or in vivo studies. Invion retains all rights to the technology, including any new IP that may emerge from the collaboration.

There is also potential for the technology to be used against oral diseases, such as periodontal disease.



For more information, you can search through Invion’s ASX announcements by clicking here.